Expressionedits Ltd

ExpressionEdits Ltd, based in Altrincham, UK, is a small, active company founded three years ago. It employs nine people and holds £1,160,640 in assets. The company operates from a virtual address, with six directors and no reported owners, and is an irregular importer of miscellaneous chemical products, with a single month of imports recorded in January 2025.

The company’s website reveals a focus on revolutionizing protein expression through genetic syntax. ExpressionEdits specializes in “intronization,” a technique that enhances gene expression without compromising design. It’s developing a “Genetic Syntax Engine,” an AI-powered platform for transgenic design, and actively seeking collaborators, particularly in gene therapy. The company has recently appointed Dr. Amrik Basran as Chief Scientific Officer and collaborated with Boehringer Ingelheim, suggesting a period of growth and partnership. Their team includes experts in RNA technologies, protein technologies, and data science, alongside advisors with academic backgrounds.

Financially, ExpressionEdits Ltd presents a mixed picture. While cash bank holdings have decreased by nearly 50% to £1,100,000, current assets have also fallen by 48% to £1,200,000. Trade debtors have increased significantly by 64%, which could be a sign of growth or potential payment issues. Retained earnings and accumulated losses have dramatically shifted, with the latter increasing by 210% to -£1,600,000. The company’s small size (meeting two of three criteria for being a small company) allows for agility, but the substantial decrease in equity raises questions. With no auditor mentioned, the figures are unaudited. It seems like ExpressionEdits is burning through cash while investing heavily in its technology and partnerships—a common pattern for startups in the biotechnology sector.

Registered in England/Wales under the registration number 13517470, with a registered address at WA14 2DT, United Kingdom, Altrincham, Cheshire, 3rd Floor 1 Ashley Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.